朱一蓓

发布时间：2020-10-14浏览次数：1751

  • 1、Yang M, Feng Y, Yue C, Xu B, Chen L, Jiang J, Lu B*, Zhu Y*. Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. PLoS One. 2018,13(3): e0193428.
  • 2、Li X, Lv Q, Feng Y, Gu Y, Xia R, Ma J, He H, Zhu Y*. Interleukin-33, a Potential Cytokine Expressed in the Tumor Microenvironment Is Involved in Antitumor Immunotherapy Through Facilitating CD8 T Cells. J Interferon Cytokine Res. 2018,38(11):491-499.
  • 3、Li G*, Yang Q*, Zhu Y*, Wang HR, Chen X, Zhang X, Lu B. T-Bet and Eomes Regulate the Balance between the Effector/Central Memory T Cells versus Memory Stem Like T Cells. PLoS One. 2013, 8(6):e67401.
  • 4、Gao X#, Zhu Y#, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X, Lu B*. TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression. PLoS One. 2012,7(2):e30676.
  • 5、Zhu Y*, Ju S*, Chen E, Dai S, Li C, Morel P, Liu L, Zhang X, Lu B. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J Immunol. 2010,185(6):3174-83
  • 6、Gao X, Wang X, Yang Q, Zhao X,...... Zhu Y*, Lu B*.Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8 T and NK Cells. J Immunol. 2015,194(1):438-45
  • 7、Zhao X, Chen X, Shen X, Tang P, Chen C, Zhu Q, Li M, Xia R, Yang X, Feng C, Zhu X, Zhu Y, Sun Z, Zhang X, Lu B, Wang X. IL-36β Promotes CD8 T Cell Activation and Antitumor Immune Responses by Activating mTORC1. Front Immunol. 2019
  • 8、Shi LR, Chen LJ, Wu CP, Zhu YB, Xu B, Zhen X, Sun MF, Wen W, Dai XC, Yang M, Lv QS, Lu BF, Jiang JT. PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses against Tumor. Clin Cancer Res. 2016,22(5): 1173-1184